Manlio Mencoboni

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer

Alfonso Cristaudo, Rudy Foddis, A Vivaldi et al. · Clinical Cancer Research · 2007 · 171 citations · Full text

Medicine, Oncology, Pathology +10

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial

Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 161 citations

Medicine, Oncology, Cancer Pharmacology +10

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)

B. Castagneto, Mario Botta, Enrico Aitini et al. · Annals of Oncology · 2007 · 139 citations · Full text

Medicine, Oncology, Pharmacology +13